8-K – 2025-11-19 – tm2531634d1_8k.htm

Fulltext

false
0000882095

0000882095

2025-11-15
2025-11-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant
to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

DATE
OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 15, 2025

 

 

 

GILEAD SCIENCES, INC.

(Exact name of registrant
as specified in its charter)

 

 

 

Delaware
0-19731
94-3047598

(State or Other Jurisdiction of

 Incorporation)
(Commission File No.)
(IRS Employer

 Identification No.)

 

333 Lakeside Drive , Foster City , California

(Address of principal executive offices)

 

94404

(Zip Code)

 

650 - 574-3000

(Registrant’s Telephone Number, Including
Area Code)

 

 

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of
the Act:

 

Title of each class:
 
Trading Symbol(s)
 
Name of each exchange on which registered

Common Stock, par value, $0.001 per share
 
GILD
 
The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ¨

 

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November
19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer
serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025. Ms. Telman’s employment
with the Company will terminate later in the month.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
GILEAD SCIENCES, INC.

 
(Registrant)

 
 

 
/s/ ANDREW D. DICKINSON

 
Andrew D. Dickinson

 
Chief Financial Officer

 

Date: November
19, 2025